BIOCRYST PHARMACEUTICALS INC (BCRX) › Cost of RevenueBIOCRYST PHARMACEUTICALS INC (BCRX) — Cost of RevenueAnnual figures by period end, from SEC filings.2009-12-31: $4.54M2010-12-31: $86.0K2016-12-31: $2.30M2017-12-31: $1.14M2019-12-31: $3.73M2020-12-31: $1.55M2021-12-31: $7.23M2022-12-31: $6.41M2023-12-31: $4.48M2024-12-31: $12.27M2025-12-31: $19.07M$19.07M2009-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$19.07M+55.5%2026-02-26From 2025-01-012024-12-31$12.27M+173.8%2026-02-26From 2024-01-012023-12-31$4.48M-30.1%2026-02-26From 2023-01-012022-12-31$6.41M-11.4%2025-02-25From 2022-01-012021-12-31$7.23M+366.4%2024-02-27From 2021-01-012020-12-31$1.55M-58.4%2023-02-27From 2020-01-012019-12-31$3.73M—2022-02-28From 2019-01-012017-12-31$1.14M-50.3%2020-03-13From 2017-01-012016-12-31$2.30M—2019-03-14From 2016-01-012010-12-31$86.0K-98.1%2013-03-11From 2010-01-012009-12-31$4.54M—2012-03-06From 2009-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)